Total Payments
$14,181
2024 Payments
$2,064
Companies
77
Transactions
773
Medicare Patients
8,820
Medicare Billing
$1.8M
Payment Breakdown by Category
Food & Beverage$13,752 (97.0%)
Education$429.13 (3.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $13,752 | 756 | 97.0% |
| Education | $429.13 | 17 | 3.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $1,638 | 111 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,149 | 66 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,052 | 57 | $0 (2024) |
| Celgene Corporation | $904.41 | 50 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $763.32 | 42 | $0 (2024) |
| Eisai Inc. | $708.06 | 37 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $631.78 | 44 | $0 (2024) |
| Incyte Corporation | $592.77 | 29 | $0 (2024) |
| Lilly USA, LLC | $482.03 | 29 | $0 (2024) |
| GlaxoSmithKline, LLC. | $399.36 | 21 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,064 | 99 | Celgene Corporation ($252.46) |
| 2023 | $2,388 | 114 | Celgene Corporation ($253.03) |
| 2022 | $1,783 | 101 | Celgene Corporation ($174.62) |
| 2021 | $1,633 | 86 | Merck Sharp & Dohme Corporation ($172.21) |
| 2020 | $1,430 | 81 | Merck Sharp & Dohme Corporation ($237.85) |
| 2019 | $1,859 | 107 | PFIZER INC. ($310.81) |
| 2018 | $1,686 | 96 | PFIZER INC. ($287.21) |
| 2017 | $1,339 | 89 | Novartis Pharmaceuticals Corporation ($223.12) |
All Payment Transactions
773 individual payment records from CMS Open Payments — Page 1 of 31
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $34.37 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $27.68 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $22.19 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 12/05/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $22.09 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $13.67 | General |
| Category: Hematology | ||||||
| 12/03/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $21.84 | General |
| 11/21/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $19.92 | General |
| Category: Oncology | ||||||
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $17.64 | General |
| 11/18/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $15.17 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Azurity Pharmaceuticals, Inc. | VIVIMUSTA (Drug) | Food and Beverage | In-kind items and services | $22.53 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $10.90 | General |
| Category: Hematology | ||||||
| 11/07/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $16.41 | General |
| Category: Immunology | ||||||
| 11/06/2024 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $24.51 | General |
| Category: BioOncology | ||||||
| 11/05/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $4.38 | General |
| Category: Hematology | ||||||
| 10/30/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $27.23 | General |
| Category: Oncology | ||||||
| 10/30/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $5.35 | General |
| Category: Oncology | ||||||
| 10/29/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Odomzo (Drug), YONSA | Food and Beverage | In-kind items and services | $19.11 | General |
| Category: Oncology | ||||||
| 10/28/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $27.85 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/24/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $25.86 | General |
| 10/23/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $19.87 | General |
| Category: Hematology/Oncology | ||||||
| 10/21/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $25.18 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Iovance Biotherapeutics, Inc. | Amtagvi (Drug) | Food and Beverage | Cash or cash equivalent | $26.22 | General |
| Category: Oncology | ||||||
| 10/16/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG, LYNPARZA | Food and Beverage | In-kind items and services | $18.97 | General |
| Category: ONCOLOGY | ||||||
| 10/15/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $21.67 | General |
| Category: Oncology | ||||||
| 10/14/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $13.17 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 24 | 1,926 | 60,432 | $948,510 | $402,299 |
| 2022 | 24 | 2,009 | 18,691 | $1.0M | $433,680 |
| 2021 | 23 | 2,058 | 16,444 | $913,856 | $410,807 |
| 2020 | 23 | 2,827 | 19,947 | $1.2M | $521,524 |
Total Patients
8,820
Total Services
115,514
Medicare Billing
$1.8M
Procedure Codes
94
All Medicare Procedures & Services
94 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 271 | 2,193 | $252,195 | $140,089 | 55.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 259 | 796 | $95,520 | $52,417 | 54.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 292 | 343 | $85,750 | $35,902 | 41.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 113 | 729 | $109,350 | $35,678 | 32.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 131 | 370 | $62,900 | $35,567 | 56.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 17 | 206 | $72,100 | $21,398 | 29.7% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 17 | 3,440 | $51,600 | $20,743 | 40.2% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 96 | 646 | $35,530 | $10,275 | 28.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 90 | 91 | $16,471 | $7,917 | 48.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 264 | 1,016 | $15,255 | $7,656 | 50.2% |
| J1756 | Injection, iron sucrose, 1 mg | Office | 2023 | 69 | 44,600 | $33,450 | $7,177 | 21.5% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 37 | 233 | $18,800 | $5,249 | 27.9% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 12 | 82 | $14,350 | $4,258 | 29.7% |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | Office | 2023 | 23 | 2,000 | $24,000 | $3,188 | 13.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 19 | 28 | $4,480 | $2,691 | 60.1% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 18 | 201 | $11,055 | $2,501 | 22.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 29 | 207 | $12,420 | $2,297 | 18.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 18 | 18 | $4,590 | $2,233 | 48.7% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 12 | 92 | $18,400 | $2,073 | 11.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 70 | 157 | $1,570 | $1,319 | 84.0% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 14 | 49 | $3,332 | $897.60 | 26.9% |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | Office | 2023 | 15 | 1,961 | $3,922 | $589.01 | 15.0% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 26 | 124 | $620.00 | $101.14 | 16.3% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 14 | 850 | $850.00 | $83.23 | 9.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 337 | 2,286 | $262,890 | $131,753 | 50.1% |
About Dr. Amir Rasheed, M.D
Dr. Amir Rasheed, M.D is a Hematology & Oncology healthcare provider based in Baytown, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/27/2007. The National Provider Identifier (NPI) number assigned to this provider is 1598952178.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Amir Rasheed, M.D has received a total of $14,181 in payments from pharmaceutical and medical device companies, with $2,064 received in 2024. These payments were reported across 773 transactions from 77 companies. The most common payment nature is "Food and Beverage" ($13,752).
As a Medicare-enrolled provider, Rasheed has provided services to 8,820 Medicare beneficiaries, totaling 115,514 services with total Medicare billing of $1.8M. Data is available for 4 years (2020–2023), covering 94 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Baytown, TX
- Active Since 09/27/2007
- Last Updated 04/08/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1598952178
Products in Payments
- KEYTRUDA (Biological) $979.02
- Lenvima (Drug) $666.51
- ELIQUIS (Drug) $488.71
- JAKAFI (Drug) $463.40
- OPDIVO (Biological) $436.59
- IBRANCE (Drug) $369.61
- BOSULIF (Drug) $366.00
- Pomalyst (Drug) $242.66
- PROMACTA (Drug) $238.88
- MONJUVI (Drug) $225.39
- JADENU (Drug) $223.68
- XTANDI (Drug) $203.37
- CALQUENCE (Drug) $203.08
- ZEJULA (Drug) $196.20
- MYLOTARG (Biological) $193.86
- VERZENIO (Drug) $191.32
- REBLOZYL (Biological) $187.29
- IMFINZI (Biological) $186.30
- INJECTAFER (Drug) $185.87
- JEVTANA (Drug) $185.33
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Baytown
Dr. Deepa Sashital, Md, MD
Hematology & Oncology — Payments: $8,832
Hematology & Oncology $8,832
Nekita Patel, Do, DO
Hematology & Oncology — Payments: $1,193
Hematology & Oncology $1,193
Dr. Kashif Ansari, M.d, M.D
Hematology & Oncology
Hematology & Oncology
Neveen Mostafa, M.d, M.D
Hematology & Oncology
Hematology & Oncology